Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Gadobutrol · 1 trial · 2 indications
Overall diagnostic preference based on global matched pairs reads according to a 3-point scale that is derived from a 5-point scale (1 = greatly prefer mangaciclanol/prefer mangaciclanol, 0 = no preference, -1 = prefer gadobutrol/greatly prefer gadobutrol), as evaluated by 3 blinded independent readers.
Lesion visualization criteria (lesion border delineation, internal morphology and degree of lesion contrast enhancement) for paired (unenhanced plus mangaciclanol-enhanced) MRIs compared to unenhanced MRI based on the primary reads on a 4-point scale (1 = poor / none; 2 = moderate; 3 = good; 4 = excellent) for up to 3 of the most representative lesions.
| Arm | Type | Description |
|---|---|---|
| Phase 2 | ACTIVE_COMPARATOR | An initial dose of 0.1 mmol/kg mangaciclanol will be compared to the standard dose of gadobutrol (0.1 mmol/kg) in Cohort 1, in approximately 60 participants. A second cohort (Cohort 2) may be initiated based on the outcome of the analysis of Cohort 1. This cohort will include approximately 60 participants (higher or lower dose), or 30 participants (same dose), depending on the dose of mangaciclanol selected for further evaluation. |
| Phase 3 mangaciclanol-gadobutrol | ACTIVE_COMPARATOR | Participants with known or highly suspected lesions of CNS or body, randomized to receive treatment sequence mangaciclanol (V2) followed by gadobutrol (V4) |
| Phase 3 gadobutrol-mangaciclanol | ACTIVE_COMPARATOR | Participants with known or highly suspected lesions of CNS or body, randomized to receive treatment sequence gadobutrol (V2) followed by mangaciclanol (V4) |
| Name | Type | Description |
|---|---|---|
| Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL | DRUG | Single intravenous (IV) administration of Mangaciclanol (GEH200486 Injection, 0.5 mmol/mL) followed by a 20mL saline flush |
| MRI Scan | DIAGNOSTIC_TEST | MRI Scan starting prior to IMP administration and continuing for up to 60 minutes post IMP administration |
| Gadobutrol | DRUG | Single intravenous (IV) administration of Gadobutrol (0.1 mmol/kg) followed by a 20mL saline flush |
Inclusion Criteria: * The participant is of legal majority age, as defined by local laws and regulations at the time of signing the ICF. * The participant is able and willing to comply with study procedures as described in the protocol. * The participant has read, understood, signed and dated the I...
Gadobutrol is an investigational small molecule being studied for use in patients with a known or highly suspected central nervous system (CNS) lesion. It is being evaluated as a contrast agent for magnetic resonance imaging (MRI) to help visualize CNS lesions in adult patients.
Gadobutrol is being developed by GE HealthCare Technologies Inc., which trades under the ticker GEHC. The company is conducting clinical research to evaluate the drug's efficacy and safety for contrast-enhanced MRI in patients with known or suspected CNS lesions.
Gadobutrol is currently in Phase 2 clinical development. It is being studied in a Phase 2/3 trial that is actively recruiting participants. The drug is investigational and has not been approved by regulatory authorities for commercial use.
Gadobutrol is being evaluated in clinical trial NCT07472491, a Phase 2/3 study on the efficacy and safety of Mangaciclanol for contrast-enhanced MRI of CNS or body in adult patients. This randomized, double-blind, active-controlled trial is recruiting 640 participants across the United States, Georgia, and Moldova.
Gadobutrol is a contrast agent used in magnetic resonance imaging (MRI). It works by enhancing the visibility of central nervous system lesions during imaging procedures, allowing for better detection and characterization of abnormalities in the brain and other CNS structures.